Список литературы

Поставить закладку

Аветисов С.Э., Егоров Е.А., Мошетова Л.К., Нероев В.В., Тахчиди Х.П. «Офтальмология. Национальное руководство. Краткое издание» – М.-«Гэотар-Медиа»-2014.-756с.
Бровкина А.Ф., Астахов Ю.С. «Руководство по клинической офтальмологии» – М. – «Медицинское информационное агентство» - 2014. – 955с.
Всемирная организация здравоохранения. Отбор и использование основных лекарственных средств. Пер. сангл. http://apps.who.int/medicinedocs/en/d/Js21434ru/
Дедов И.И.,Шестакова М.В. «Алгоритмы специализированной медицинской помощи больным сахарным диабетом», 7-й выпуск // Сахарный диабет (спецвыпуск №1).-М.- 2015.- 111с.
Инструкция по применению лекарственного препарата для медицинского применения Луцентис от 15.02.2014г.
Инструкция по медицинскому применению лекарственного препарата Озурдексот 28.03.2016.
Инструкция по применению лекарственного препарата для медицинского применения Эйлеа от 29.03.2016.
Boyer D.S., Yoon Y., Belfort R., Jr. et al. Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology.2014; 121: 1904-1914
Brown DM, Schmidt-Erfurth U., Do DV et al. Intravitrealaflibercept for diabetic macular edema. 100 week results from the VISTA and VIVID studies. Ophthalmology. 2015; 122:1-9.
Callanan DG, Gupta S, Boyer DS et al. Ozurdex PLACID Study Group. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013;120(9):1843-51.
Diabetes Control and Complication Trial Research Group. The effect of intensive treatment ofdiabetes on the development and progression of long-term complication in insulin dependent diabetes mellitus // N. Engl. J. Med.- 1993.- V. 329.- P. 977-86.
Diabetes Control and Complication Trial Research Group. The relationship of glycemic exposure (HbA1с) to the risk of development and progression of retinopathy in the Diabetes Control and Complication Trial // Diabetes.-1995.- V. 44.- P.- 968-983.
Diabetic Retinopathy Clinical Research Network. Elman M.J., Aiello L.P., Beck R.W. et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema // Ophthalmology. – 2010. – Vol. 117, N 6. – P.1064-1077
Diabetic Retinopathy Clinical Research Network, Elman M.J., Qin H., Aiello L.P. et al. Intravitrealranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology.2012; 119 (11): 2312-2318.
Diabetic Retinopathy Clinical Research Network. Wells JA, Glassman AR, Ayala AR et al.Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015; 372: 1193-1203
Diabetic Retinopathy Study Research Group. Report No 8.Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study (DRS) findings // Ophthalmology.- 1981.- V. 88.- P. 583-600.
Diabetic Retinopathy Study Research Group. Report No 14. Indications for photocoagulation treatment of diabetic retinopathy //Int. Ophthalmol. Clin.- 1987.- V. 27.- P. 239-252.
Do D.V., Nguyen Q.D, Boyer D, et al. One-year outcomes of the DA Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012; 119: 1658-1665.
Do D.V., Schmidt-Erfurth U., Gonzalez V.H, et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011; 118: 1819-1826.
Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS reportNo 9 // Ophthalmology.- 1991.- V.98.- P. 766-785.
Elman M.J., Ayala A., Bressler N.M. et al.; Diabetic Retinopathy Clinical Research Network. IntravitrealRanibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015; 122 (2): 375-381.
Haller J. A., Kuppermann B. D., Blumenkranz M. S. et al.; Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch. Ophthalmol. 2010; 128 (3): 289-296.
Henry E. Wiley, Darby J.S. Thompson, Clare Bailey, Emily Y. Chew, et al. A Crossover Design for Comparative Efficacy: A 36-WeekRandomized Trial ofBevacizumab and Ranibizumab for Diabetic Macular Edema.// Ophthalmology. 2016 Apr; 123(4): 841–849.
Jampol, Glassman, Bressler, Wells, Ayala; Diabetic Retinopathy Clinical Research Network. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial. // JAMA Ophthalmol. 2016 Dec 1;134(12).
John A. Wells, Adam R. Glassman, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology 2016; 123(6):1351-1359.
Keech A.C., Mitchell P., Summanen P.A. et al. FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial // Lancet.- 2007.- V. 370.- P. 1687-1697.
Keech A.C., Simes R.J., Barter P. et al. FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial // Lancet.- 2005.- V. 366.- P. 1849-1861.
Klein R., Klein B.E.K., Moss S.E. et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years // Arch Ophthalmol.-1984.- V. 102.- P. 520-526.
Klein R., Klein B.E.K., Moss S.E. et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 ormore years // Arch Ophthalmol.- 1984.- V. 102.- P. 527-532.
Klein R., Klein B.E.K., Moss S.E. et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XI. Theincidenceofmacularedema //Ophthalmology.- 1989.- V. 96.- P.1501-1510.
Małgorzata W., Diana D., Agnieszka B., Zofia M. Bevacizumabintravitreal injections in the treatment of diabetic macular oedema. KlinOczna. 2013;115(1):15-9
Massin P., Bandello F., Garweg J.G. et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study // Diabetes Care. – 2010. – V. 33, N 11. – P.2399-2405.
Mitchell P., Bandello F., Schmidt-Erfurth U. The RESTORE study: ranibizumabmonotherapy or combined with laser versus laser monotherapy for diabetic macular edema // Ophthalmology.- 2011.- V. 118, N. 4.- P. 615-25.
Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012; 15: 171–185.
Porta M, Kohner EM, Screening for diabetic retinopathy in Europe // Diabetic Medicine.-1991.- V. 8.- P. 197-198.
SchieldsМ.В.Glaucoma in diabetic patients / In: Ocular problems in diabetes mellitus / - Blackwell Scientific Publ.- Boston.- 1992.- P. 307-319.
SibelDemirel, Colby Argo, AniruddhaAgarwal, Jacob Parriott, et al. Updates on the Clinical Trials in Diabetic Macular Edema. // Middle East Afr J Ophthalmol. 2016 Jan-Mar; 23(1): 3–12.
Stephenson J., Fuller J.H. and EURODIAB IDDM Complications Study. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study // Diabetologia.- 1994.- V. 37.- P. 278-285.
Stratton I.M., Kohner E.M., Aldington S.J. et al. UKPDS 50: risk factors for incidence and progression of diabetic retinopathy in type 2 diabetes over 6 years from diagnosis // Diabetologia.- 2001.- V. 44.- P. 156-163.
UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33 // Lancet.-1998.- V. 352.- P. 837-853.
Wells, Glassman, Jampol, Aiello, Antoszyk, Baker, et al. Diabetic Retinopathy Clinical Research Network. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.// JAMA Ophthalmol. 2016 Feb;134(2):127-34.
WHO. Prevention of blindness from diabetes mellitus // Report of a WHO consultation in Geneva 9-11 November 2005.- Switzerland.- WHO press.- 2005.- 39 p.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница